American Heart Journal
Volume 156, Issue 3 , Pages 528-536.e5 , September 2008

Baseline characteristics of patients with diabetes and coronary artery disease enrolled in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial

  • The BARI 2D Study Group

      Affiliations

    • BARI 2D sites and Study Group are listed in the Appendix A available online.Reprint requests: Maria Mori Brooks, PhD, University of Pittsburgh, GSPH, A530 Crabtree Hall, Pittsburgh, PA 15261.Email: mbrooks@pitt.edu

Received 11 February 2008 ,Accepted 16 May 2008.

References 

  1. The BARI Investigators  . Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. N Engl J Med. 1996;335:217–225
  2. UK Prospective Diabetes Study (UKPDS) Group . Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854–865
  3. Chiquette E , Ramirez G , DeFronzo R . A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med. 2004;164:2097–2104
  4. Gu K , Cowie CC , Harris MI . Diabetes and decline in heart disease mortality in US adults. JAMA. 1999;281:1291–1297
  5. Eagle KA , Guyton RA , Davidoff R, et al.   American College of Cardiology; American Heart Association. ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery). Circulation. 2004;110:e340–e437
  6. Smith SC , Feldman TE , Hirshfeld JW, et al.   ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). Circulation. 2006;113:156–175
  7. Brooks MM , Frye RL , Genuth S, et al.   Hypotheses, design and methods for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Am J Cardiol. 2006;97(Suppl):9G–19G
  8. Magee MF , Isley WL . Rationale, design and methods for glycemic control in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Am J Cardiol. 2006;97(Suppl):20G–30G
  9. Barsness GW , Gersh BJ , Brooks MM, et al.   Rationale for the revascularization arm of the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Am J Cardiol. 2006;97(Suppl):31G–40G
  10. Albu J , Gottlieb SH , August P, et al.   Modifications of coronary risk factors. Am J Cardiol. 2006;97(Suppl):41G–52G
  11. Alderman EL , Stadius M . The angiographic definitions of the Bypass Angioplasty Revascularization Investigation. Coronary Artery Disease. 1992;2:1189–1207
  12. Feldman EL , Stevens MJ , Thomas PK, et al.   A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care. 1994;11:1281–1289
  13. McGill JB , Schneider DJ , Arfken CL, et al.   Factors responsible for impaired fibrinolysis in obese patients. Diabetes. 1994;43:104–109
  14. Imperatore G , Cadwell BL , Geiss L, et al.   Thirty-year trends in cardiovascular risk factor levels among US adults with diabetes: National Health and Nutrition Examination Surveys, 1971-2000. Am J Epidemiol. 2004;160:531–539
  15. Clinical trials.gov. Comparison of two treatments for multivessel coronary artery disease in individuals with diabetes (FREEDOM). Available at http://clinicaltrials.gov/ct/show/NCT00086450 Last accessed October 28, 2007
  16. Clinical trials.gov. Coronary Artery Revascularization in Diabetes (VACARD). Available at http://clinicaltrials.gov/show/NCT00326196 Last accessed October 28, 2007
  17. Kapur A , Malik IS , Bagger JP, et al.   The Coronary Artery Revascularisation in Diabetes (CARDia) trial: background, aims, and design. Am Heart J. 2005;149:13–19
  18. Gregg EW , Qiuping G , Cheng YJ, et al.   Mortality trends in men and women with diabetes, 1971 to 2000. Ann Intern Med. 2007;147:149–155
  19. Kanaya A , Grady D , Barrett-Connor E . Explaining the sex difference in coronary heart disease mortality among patients with type 2 diabetes mellitus: a meta-analysis. Arch Intern Med. 2002;162:1737–1745
  20. Charbonnel B , Dormandy J , Erdman E, et al.   The Prospective Pioglitazone Clinical Trial in Macrovascular Events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5,238 patients. Diabetes Care. 2004;27:1647–1653
  21. Boden WE , O'Rourke RA , Teo KK, et al.   Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356:1503–1516
  22. ADVANCE Collaborative Group . ADVANCE—Action in Diabetes and Vascular Disease: patient recruitment and characteristics of the study population at baseline. Diabet Med. 2005;22:882–888
  23. Clinical trials.gov. Action to Control Cardiovascular Risk in Diabetes (ACCORD). Available at http://clinicaltrials.gov/ct/show/NCT00000620 Last accessed March 31, 2007

 Writing group: Maria Mori Brooks, Gregory Barsness, Bernard Chaitman, Sheng-Chia Chung, David Faxon, Frederick Feit, Robert Frye, Saul Genuth, Jennifer Green, Mark Hlatky, Sheryl Kelsey, Frank Kennedy, Ronald Krone, Richard Nesto, Trevor Orchard, Robert O'Rourke, Charanjit Rihal, Jean-Claude Tardif.

 BARI 2D is funded by the National Heart, Lung, and Blood Institute and the National Institute of Diabetes and Digestive and Kidney Diseases (U01 HL061744, U01 HL061746, U01 HL061748, U01 HL063804).

 BARI 2D receives significant supplemental funding from GlazoSmithKline (Collegeville, PA); Bristol-Myers Squibb Medical Imaging, Inc. (North Billerica, MA); Astellas Pharma US, Inc. (Deerfield, IL); Merck & Co., Inc. (Whitehouse Station, NJ); Abbott Laboratories, Inc. (Abbott Park, IL); and Pfizer, Inc (New York, NY), and generous support from Abbott Laboratories Ltd.; MediSense Products (Mississauga, Ontario, Canada); Bayer Diagnostics (Tarrytown, NY); Becton, Dickinson and Company (Franklin Lakes, NJ); J. R. Carlson Labs (Arlington Heights, IL); Centocor, Inc. (Malvern, PA); Eli Lilly and Company (Indianapolis, IN); LipoScience, Inc. (Raleigh, NC); Merck Sante (Lyon, France); Novartis Pharmaceuticals Corporation (East Hanover, NJ); and Novo Nordisk, Inc. (Princeton, NJ).

PII: S0002-8703(08)00387-6

doi: 10.1016/j.ahj.2008.05.015

American Heart Journal
Volume 156, Issue 3 , Pages 528-536.e5 , September 2008

Article Tools

* Image Usage & Resolution